Drugs / Bivamelagon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07156578 | Nov 2025 → Apr 2028 expected | acquired hypothalamic obesity | Rhythm Pharmaceuticals, Inc. | Enrolling by invitation | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Rhythm Pharmaceuticals, Inc. | Results Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 rhythmtx.com ↗
Bivamelagon therapy achieved progressive reductions in BMI and hunger measures in patients (N=26) with acquired HO at one year |
| 2025-07-12 | Rhythm Pharmaceuticals, Inc. | Results Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 rhythmtx.com ↗
In the 14-week, double-blind, four-arm, placebo-controlled portion of the trial, bivamelagon achieved statistically significant and clinically meaningful reductions in body mass index (BMI), consistent with BMI reductions achieved with setmelanotide therapy |
| 2025-07-09 | Rhythm Pharmaceuticals, Inc. | Results Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity rhythmtx.com ↗
Bivamelagon achieved statistically significant and clinically meaningful reductions in body mass index (BMI) at 14 weeks of treatment, consistent with BMI reductions achieved with setmelanotide therapy in similar patient populations in past trials. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Rhythm Pharmaceuticals, Inc. | Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 rhythmtx.com ↗ |
| 2025-07-12 | Rhythm Pharmaceuticals, Inc. | Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 rhythmtx.com ↗ |
| 2025-07-09 | Rhythm Pharmaceuticals, Inc. | Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity rhythmtx.com ↗ |
| 2025-07-08 | Rhythm Pharmaceuticals, Inc. | Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity rhythmtx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivamelagon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07156578 ↗ |
| Modality | Small molecule | — CHEMBL5314508 ↗ |
| Route | Oral | “daily dose of oral bivamelagon” NCT07156578 ↗ |